Research programme: excitatory amino acid receptor modulators - Eli Lilly

Drug Profile

Research programme: excitatory amino acid receptor modulators - Eli Lilly

Alternative Names: LY-457691; LY-458545; LY-467711; LY-525327

Latest Information Update: 27 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly; NPS Pharmaceuticals
  • Class
  • Mechanism of Action Excitatory amino acid agonists; Excitatory amino acid antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurological disorders; Pain

Most Recent Events

  • 29 Nov 2000 The collaboration between Eli Lilly and NPS Allelix has expired, giving Eli Lilly full rights to the programme
  • 30 Dec 1998 Eli Lilly and NPS Allelix are collaborating on the development of compounds which target excitatory amino acid receptors
  • 30 Dec 1998 Preclinical development for Neurological disorders in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top